Multidrug resistant HIV-1 infection

Active Ingredient: Lenacapavir

Indication for Lenacapavir

Population group: only adults (18 - 65 years old)
Therapeutic intent: Curative procedure

Lenacapavir tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen, for oral loading prior to administration of long-acting lenacapavir injection

For this indication, competent medicine agencies globally authorize below treatments:

600 mg once daily on the first 2 days and 300 mg once daily on the 8th day

For:

Route of admnistration

Oral

Defined daily dose

300 - 600 mg

Dosage regimen

From 300 To 600 mg once every day

Loading dose

600 mg

Detailed description

Initiation of treatment with lenacapavir requires lenacapavir film-coated tablets to be taken as oral loading prior to administration of lenacapavir injection.

Initiation

On treatment Day 1 and Day 2, the recommended dose of lenacapavir is 600 mg per day taken orally. On treatment Day 8, the recommended dose is 300 mg taken orally. Then, on treatment Day 15, the recommended dose is 927 mg administered by subcutaneous injection.

Table 1. Recommended treatment regimen for lenacapavir: initiation:

Treatment time Dose of lenacapavir: initiation
Day 1 600 mg orally (2 × 300 mg tablets)
Day 2 600 mg orally (2 × 300 mg tablets)
Day 8 300 mg orally (1 × 300 mg tablet)
Day 15 927 mg subcutaneous injection (2 × 1.5 mL injectionsa)

a Two injections, each at a separate site in the abdomen.

Missed dose

If the Day 2 (600 mg) oral dose is missed by:

  • less than 6 days, the patient should take 600 mg as soon as possible, and 300 mg by Day 8.
  • 6 days or more, the patient should take 600 mg as soon as possible, and 300 mg on Day 15.

If the Day 8 (300 mg) oral dose is missed by:

  • less than 6 days, the patient should take 300 mg as soon as possible.
  • 6 days or more, the patient should take 300 mg on Day 15.

Regardless of when the Day 2 or Day 8 oral dose is being taken, subcutaneous injection should be administered on Day 15 as described in Table 1.

If the patient vomits within 3 hours of taking an oral dose of lenacapavir, another oral dose should be taken. If the patient vomits more than 3 hours after taking an oral dose of lenacapavir there is no need to take another oral dose of lenacapavir, and the scheduled dosing regimen should continue.

Dosage considerations

Lenacapavir tablets should be taken orally with or without food.

927 mg on day 15th, then 927 mg once every 6 months

For:

Route of admnistration

Subcutaneous

Defined daily dose

927 - 927 mg

Dosage regimen

From 927 To 927 mg once every 180 day(s)

Detailed description

Initiation

On treatment Day 1 and Day 2, the recommended dose of lenacapavir is 600 mg per day taken orally. On treatment Day 8, the recommended dose is 300 mg taken orally. Then, on treatment Day 15, the recommended dose is 927 mg administered by subcutaneous injection.

Oral tablets can be taken with or without food (see lenacapavir tablet SmPC.

Maintenance

The recommended dose is 927 mg of lenacapavir administered by subcutaneous injection once every 6 months (26 weeks) from the date of the last injection (+/- 2 weeks).

Table 1. Recommended treatment regimen for lenacapavir: initiation and maintenance dosing schedule:

Treatment time  
 Dose of lenacapavir: initiation
Day 1 600 mg orally (2 × 300 mg tablets)
Day 2 600 mg orally (2 × 300 mg tablets)
Day 8 300 mg orally (1 × 300 mg tablet)
Day 15 927 mg subcutaneous injection (2 × 1.5 mL injectionsa)
 Dose of lenacapavir: maintenance
Every 6 Months
(26 weeks)b
+/- 2 weeks
927 mg subcutaneous injection (2 × 1.5 mL injectionsa)

a Two injections, each at a separate site in the abdomen.
b From the date of the last injection.

Missed dose

During the maintenance period, if more than 28 weeks have elapsed since the last injection and if clinically appropriate to continue lenacapavir treatment, the regimen should be restarted from Day 1 (see table 1).

Dosage considerations

Lenacapavir injections should be administered into the abdomen (two injections, each at a separate site) by a healthcare professional.

Active ingredient

Lenacapavir

Lenacapavir is a multistage, selective inhibitor of HIV-1 capsid function that directly binds to the interface between capsid protein (CA) subunits. Lenacapavir inhibits HIV-1 replication by interfering with multiple, essential steps of the viral lifecycle, including capsid-mediated nuclear uptake of HIV-1 proviral DNA, virus assembly and release, and capsid core formation.

Read more about Lenacapavir

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.